NCT01657461View on ClinicalTrials.gov

Solitaire™ With the Intention For Thrombectomy as PRIMary Endovascular Treatment (SWIFT PRIME) Trial

NACompletedINTERVENTIONAL

Enrollment

196

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

January 31, 2015

Study Completion Date

January 31, 2015

Conditions

Acute Ischemic Stroke

Interventions

DRUG

Intravenous (IV) recombinant human tissue plasminogen activator (rtPA)

Standard therapy with Intravenous (IV) recombinant human tissue plasminogen activator (rtPA)

DEVICE

Solitaire revascularization device

Clot retrieval with the Solitaire revascularization device after patients have received standard therapy with intravenous tissue plasminogen activator

Trial Locations (1)

14203

Kaleida Health/Buffalo General, Buffalo

All Listed Sponsors

lead

Medtronic Neurovascular Clinical Affairs

INDUSTRY

NCT01657461 - Solitaire™ With the Intention For Thrombectomy as PRIMary Endovascular Treatment (SWIFT PRIME) Trial | Biotech Hunter | Biotech Hunter